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bjectives We sought to identify baseline clinical, angiographic, and hemodynamic variables associ-
ted with optimal bare-metal stent (BMS) deployment, allowing selection of patients for treatment
ith BMS.
ackground Patients with fractional ﬂow reserve (FFR) 0.90 after BMS have low (6%) major ad-
erse cardiac event rates (MACE). We hypothesized that baseline variables can predict post-stent FFR
0.90 and MACE after BMS.
ethods In 586 patients from the multicenter post-BMS FFR registry, we developed multivariable
ogistic regression models to identify clinical, angiographic, and hemodynamic variables associated
ith post-stent FFR 0.90 and 6-month MACE.
esults After adjusting for potential confounders, baseline FFR (odds ratio [OR]: 5.0) and stent di-
meter (OR: 2.5 per millimeter) were predictive of post-stent FFR 0.90. Lower FFR (OR: 7.8); smaller
tent diameter (OR: 3.7 per millimeter); longer stent length (OR: 1.0 per millimeter); and larger mini-
al luminal diameter (OR: 2.2 per millimeter) were predictors of MACE. In patients receiving 3-mm
iameter stents, baseline FFR 0.70 yielded signiﬁcantly higher likelihood of achieving post-stent
FR 0.90 than baseline FFR 0.70 (77% vs. 63%, p  0.05); and in patients receiving 3-mm di-
meter stents, baseline FFR 0.50 was associated with higher MACE than FFR 0.50 to 0.70, and FFR
0.70 (40% vs. 15% vs. 13%, p  0.05).
onclusions In patients receiving BMS, baseline FFR and stent diameter are predictors of post-stent
FR 0.90; and baseline FFR, stent diameter, stent length, and minimal luminal diameter are predic-
ors of MACE. These variables may allow selection of patients who will have excellent results with
MS. (J Am Coll Cardiol Intv 2009;2:357–63) © 2009 by the American College of Cardiology
oundation
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358rug-eluting stents (DES) have resulted in a significant
eduction in restenosis. However, there are continued con-
erns about late stent thrombosis (1–8), need for prolonged
ual antiplatelet therapy, and higher DES cost compared
ith bare-metal stents (BMS).
See page 364
Fractional flow reserve (FFR) is defined as the maximal
ow through a vessel in the presence of a stenosis divided by
he maximal achievable flow through the vessel in the
heoretic absence of the stenosis (9,10). Although FFR is
ost often clinically used to determine the significance of
oderate coronary lesions (11), it can also be used to
ptimize percutaneous coronary intervention (PCI) (12–
5). We have previously shown that low major adverse
ardiac events (MACE) rates (6%) can be obtained after
CI with BMS in patients who achieve post-stent FFR of
0.90 (16).
Because post-stent FFR 0.90
is a useful surrogate for favorable
long-term clinical outcome after
BMS deployment, a model pre-
dicting post-stent FFR 0.90
using variables available to the
operator prior to stent selection
could identify patients with
high probability of optimal
stent deployment using BMS.
Thus, we hypothesized that a
model comprising baseline clin-
ical, angiographic, and hemody-
namic variables can predict a
post-stent FFR 0.90 and
MACE.
ethods
tudy population. The current analysis is derived from the
ost-stent FFR registry, a multicenter registry of 750
atients from 15 hospitals (5 centers in the U.S., 5 in
urope, and 5 in Asia) who underwent PCI with BMS
etween January 2000 and April 2001, in which the pressure
ire was used (16). The reason for use of the pressure wire
as either for assessment of moderate lesions or to guide
CI. Thus, the present study population consisted of 586 of
50 patients with complete clinical, baseline FFR, post-
tent FFR, and angiographic data; 164 patients were ex-
luded from the study for the following incomplete vari-
bles: baseline FFR (n  105), minimum lumen diameter
MLD) (n  25), diabetic status (n  12), artery investi-
ated (n  31), and stent diameter (n  7).
nterventional procedure and measurement of FFR. Follow-
bbreviations
nd Acronyms
TP  adenosine
riphosphate
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
FR  fractional flow
eserve
ACE  major adverse
ardiac event(s)
LD  minimal luminal
iameter
CI  percutaneous
oronary interventionng angiography, FFR was determined using a 0.014-inch oensor-tipped high-fidelity Pressure Wire (RADI Medical,
ppsala, Sweden) in all patients as previously described
17). The pressure transducer was placed distal to the
tenosis in question. Simultaneous distal coronary and aortic
ressures were recorded at baseline and during maximal
yperemia. Hyperemia was induced by 1 of the following
egimens: intracoronary adenosine or adenosine triphos-
hate (ATP), 30 g in the right coronary artery and 40
g in the left coronary artery; intravenous adenosine or
TP at 140 g/kg/min; or intracoronary papaverine (15 mg
or the right coronary artery and 20 mg for the left coronary
rtery), as previously described (16). The hyperemic capacity
f these various drugs used has been shown to be equivalent
18,19). Fractional flow reserve was calculated as the ratio of
he mean distal intracoronary pressure to mean aortic
ressure at the time of peak hyperemia. Percutaneous
oronary intervention was performed with BMS according
o operator preference. The FFR measurements were made
istal to the stenosis. All patients underwent successful PCI
10% residual angiographic diameter stenosis by visual
nalysis), followed by post-stent FFR measurement. Quan-
itative coronary angiography was performed offline in all
atients. Optimal post-stent FFR, defined as an FFR0.90
ased on favorable outcome data from the stent registry
16), and MACE represented the 2 end points of this study.
e defined MACE as 6-month death, myocardial infarc-
ion, or target vessel revascularization. Procedural anti-
hrombotic, antiplatelet, and other therapy was according
he local routine of participating centers.
tatistical analysis. Clinical characteristics and angiographic
nd hemodynamic data were compared by univariate anal-
sis between patients who achieved optimal post-stent FFR
0.90 and those with post-stent FFR 0.90. Continuous
ariables were compared using a t-test, and categorical
ariables were compared with the chi-square tests. Multi-
ariable analyses were performed using logistic regression
odels with optimal post-stent FFR 0.90 and MACE as
he dependent variables. When MACE was used as the
ependant variable, post-stent FFR data were excluded
rom the multivariable analysis as this variable would not be
vailable to the operator at the time of stent selection. All
vailable variables were considered for the initial model,
ncluding patient demographics and medical history (age,
ypertension, diabetes, hypercholesterolemia, smoking,
amily history of heart disease), and angiographic and
emodynamic variables (vessel location, reference diameter,
iameter stenosis, MLD, stent diameter, stent length, and
aseline FFR). Variables with p  0.05 on univariate
nalysis were included in the multivariate analysis, except
eference diameter, which was excluded because it reflected
tent diameter (included in the model). Diabetes and
ypercholesterolemia were added to the multivariable model
s they were important clinical variables that might impact
utcome. Odds ratios (OR), 95% confidence intervals (CI),
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359nd p values for a post-stent FFR 90 and MACE were
alculated from these models. Receiver-operator character-
stic analysis was performed. All analyses were performed
sing SAS software version 9.1 (SAS Institute Inc., Cary,
orth Carolina). A p value of 0.05 was considered
ignificant, and all tests were 2-tailed.
esults
he distribution of diameter stenosis, baseline FFR, stent
iameter, and reference diameter in study patients is shown
n Figure 1. The mean post-stent diameter stenosis was 8.1
10.4% and the mean post-stent FFR was 0.92  0.07.
yperemia was induced for FFR measurement using intra-
oronary adenosine or ATP in 57%, intravenous adenosine
r ATP in 31%, and intracoronary papaverine in 12% of
atients. Of 586 patients, 424 (72%) achieved a post-stent
FR 0.90.
There were no significant differences in age or clinical risk
actors, MLD, diameter stenosis, stent length, or maximal
nflation pressure used for PCI between patients with
ost-stent FFR 0.90 and those with post-stent FFR
0.90 (Table 1). There were greater numbers of left
ircumflex arteries (17% vs. 9%, p  0.02) and fewer left
nterior descending arteries (49% vs. 64%, p  0.01) in
atients with post-stent FFR 0.90 than in those with
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Figure 1. Distribution of Baseline Angiographic and Hemodynamic Variable
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) (B), stent diameter in millimeters (SD) (C), and reference diameter in millimetersost-stent FFR 0.90. Furthermore, significantly largerTable 1. Baseline Patient Characteristics in Patients With Post-Stent
FFR >0.90 or <0.90
Post-Stent FFR
>0.90
(n  424)
Post-Stent FFR
<0.90
(n  162) p Value
Mean age, yrs 62 10 61 11 NS
Smoking, % 48 48 NS
Hypertension, % 52 54 NS
Diabetes, % 24 27 NS
Hypercholesterolemia, % 62 62 NS
Family history of CAD, % 36 34 NS
LAD, % 49 64 0.01
RCA, % 33 43 NS
LCx, % 17 9 0.02
Reference diameter, mm 3.08 0.63 2.92 0.53 0.01
Diameter stenosis, % 73 15 73 17 NS
Minimal luminal
diameter, mm
0.81 0.49 0.76 0.50 NS
Stent diameter, mm 3.3 0.5 3.15 0.6 0.01
Stent length, mm 17.5 7.5 18.4 9.5 NS
Baseline FFR 0.62 0.17 0.58 0.15 0.01
Post-stent FFR 0.95 0.05 0.84 0.07 —
Maximum inﬂation
pressure, mm Hg
12.3 2.6 12.4 2.8 NS
CAD  coronary artery disease; FFR  fractional flow reserve; LAD  left anterior descending;LCx left circumflex artery; NS not significant; RCA right coronary artery.
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360eference diameter (3.08  0.63 mm vs. 2.92  0.53 mm),
tent diameter (3.3  0.5 mm vs. 3.15  0.6 mm), and
igher baseline FFR (0.62  0.17 vs. 0.58  0.15) were
bserved (p  0.01 for all) in patients with post-stent FFR
0.90 than in those with post-stent FFR 0.90.
As in the post-stent registry (16), we observed a signifi-
antly greater incidence of MACE in patients with post-
tent FFR 0.90 versus those with post-stent FFR 0.90
19.1% vs. 5.7%, p  0.0001) (Table 2). This finding was
riven by higher rates of myocardial infarction (4.9% vs.
.9%, p  0.0023), coronary artery bypass graft (5.5% vs.
.9%, p  0.0007), and PCI (9.3% vs. 4.0%, p  0.012) in
atients with post-stent FFR 0.90. There were no signif-
cant differences in death between the 2 groups (0.6 vs.
.7%, p  NS) (Fig. 2).
In the multivariate model using post-stent FFR 0.90 as
he dependent variable, higher baseline FFR (OR: 5.0,
Table 2. MACE According to Whether a Post-Stent FFR <0.90 or <0.90
Was Achieved
Post-Stent FFR
>0.90
(n  424)
Post-Stent FFR
<0.90
(n  162) p Value
Death 3 (0.7%) 1 (0.6%) NS
Myocardial infarction 4 (0.9%) 8 (4.9%) 0.001
Revascularization 21 (4.9%) 24 (14.8%) 0.001
CABG 4 (0.9%) 9 (5.5%) 0.001
PCI 17 (4.0%) 15 (9.3%) 0.01
Any MACE 24 (5.7%) 31 (19.1%) 0.001
CABG  coronary artery bypass graft surgery; MACE  major adverse cardiac events; PCI 
percutaneous coronary angioplasty; other abbreviations as in Table 1.
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Figure 2. Proportion of Patients Achieving Post-Stent FFR >0.90 AccordinLikelihood of achieving post-stent FFR 0.90 according to SD and baseline FFR. NSFR: 0 to 1.0, 95% CI: 1.6 to 15.6) and larger stent
iameter (OR: 2.5 per millimeter, 95% CI: 1.5 to 4.0) were
ignificant predictors of post-stent FFR 0.90 (Table
).There was a trend toward lower likelihood of achieving
ptimal post-stent FFR 0.90 in the left anterior descend-
ng artery versus the right coronary artery (0.70, 95% CI:
.40 to 1.0). When baseline FFR was considered by
ecreasing increments of 0.1, the OR was 1.16 (95% CI: 1.0
o 1.3).
In the multivariate model using MACE as the dependent
ariable, lower baseline FFR (OR: 7.8, FFR: 0 to 1.0, 95%
I: 1.3 to 48.0), smaller stent diameter (OR: 3.7 per
illimeter, 95% CI: 1.7 to 8.0), larger MLD (OR: 2.2 per
illimeter, 95% CI: 1.2 to 4.0), and longer stent length
OR: 1.0 per millimeter, 95% CI: 1.0 to 1.1) were significant
redictors of MACE (Table 4). When baseline FFR was
onsidered by decreasing increments of 0.1, the OR was 1.23
95% CI: 1.0 to 1.5). The receiver-operator characteristic
nalysis indicated that the C statistic for this model was 0.67.
72%
85%
71%
95%
82%
87%
 Stent Diameter 
3.5 mm
Stent Diameter 
4.0 mm
 
 
d 
P=NS 
P=NS 
aseline FFR and SD
Table 3. Model Predicting Post-Stent FFR >0.90
OR 95% CI p Value
Baseline FFR (0 to 1.0) 5.0 1.6–15.6 0.01
Stent diameter, per mm 2.5 1.5–4.0 0.001
Artery revascularized
LAD vs. RCA 0.7 0.4–1.0 0.02
LCx vs. RCA 1.4 0.7–2.7 NS
Diabetes 1.1 0.7–1.7 NS
Hypercholesterolemia 1.2 0.8–1.8 NS
CI confidence interval; OR odds ratio; other abbreviations as in Table 1.eter
trend
trend
 tren
 
g to B not signiﬁcant; other abbreviations as in Figure 1.
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361We sought to further define the relationship between
tent diameter, baseline FFR, and the 2 dependant vari-
bles: post-stent FFR0.90 and MACE. We found that in
atients with stent diameter of 3 mm, those with baseline
FR 0.7 had significantly greater likelihood of achieving
ost-stent FFR 0.90 compared with those with baseline
FR 0.5 and 0.50 to 0.70 (77% vs. 63% vs. 63%,
espectively, p  0.05). The value of baseline FFR 0.70
or predicting a high likelihood of achieving post-stent FFR
0.90 was not observed in patients with stent diameter less
han or greater than 3 mm (Fig. 2). Interestingly, in patients
ith stent diameter 3 mm, baseline FFR 0.50 was
ssociated with significantly greater MACE than FFR 0.50
o 0.70, and FFR 0.70 (40% vs. 15% vs. 13%, p  0.05).
owever, MACE was not significantly different in patients
ith baseline FFR 0.50 to 0.70 and 0.70 among patients
ith stent diameter 3 mm (Fig. 3).
iscussion
n the present study, using variables available to the operator
rior to BMS deployment, we demonstrate that baseline
FR and stent diameter are independently predictive of
Table 4. Model Predicting MACE
OR 95% CI p Value
Baseline FFR (1.0 to 0)* 7.8 1.3–48.0 0.02
Stent diameter, per mm* 3.7 1.7–8.0 0.001
MLD, per mm 2.2 1.2–4.0 0.01
Stent length, per mm 1.0 1.0–1.1 0.01
*Decreasing values of these variables predict MACE.
MLDminimal luminal diameter; other abbreviations as in Tables 2 and 3.
40%
10%
15% 14%13%
7
0%
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20%
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40%
50%
Stent Diameter < 3.0 mm Stent Diameter 3
% MACE
NS
P<0.05
Figure 3. Incidence of MACE According to Baseline FFR and SDIncidence of major adverse cardiac event (MACE) rates according to SD and baselineost-stent FFR 0.90, and baseline FFR, stent diameter,
LD, and stent length are significant predictors of
ACE. In patients receiving 3-mm diameter stents with
aseline FFR 0.70, the likelihood of achieving post-stent
FR 0.90 was 77%, similar to patients receiving 3.5-mm
iameter stents. In addition, among patients receiving
3-mm diameter stents, those with baseline FFR 0.50
ad significantly higher MACE rates than those with FFR
0.50. Thus, FFR and stent dimensions may be of value in
electing lesions that can be revascularized using BMS with
xcellent long-term MACE rates.
There are several potential explanations for the predictive
alue of baseline FFR and stent diameter for optimal
ost-stent FFR and MACE in patients receiving BMS.
First, the lesion characteristics that reflect a higher (albeit
schemic) baseline FFR and larger stent diameter, namely,
ess severe stenoses, less lesional plaque burden, and larger
eference vessel diameter result in larger post-stent minimal
uminal areas, better stent expansion, and strut apposition
20). Post-stent FFR has been shown to correlate with
ost-stent intravascular ultrasound minimal luminal area,
ith neither correlating well with angiography (14). In
upport of the argument that vessels with lower atheroma
urden accommodating larger BMS have good outcome, a
ecent study of 233 patients receiving BMS with diameters
3.5 mm had similar rates of MACE to 233 propensity
atched patients treated with DES (7.7% vs. 8.5%, p 
S) (21).
Second, higher baseline FFR indicates less burden of
theroma in the whole vessel, particularly angiographically
nappreciated atheroma proximal to the stented site. Thus,
atients with higher baseline FFR may have less vulnerable
laques proximal to the stented site resulting in lower
6%
0%
11%
5%
9%
3%
Stent Diameter 3.5 mm Stent Diameter 4.0 mm
re Stent FFR < 0.5
re Stent FFR 0.5-0.7
re Stent FFR > 0.7
NS
P<0.001 for trend
P=NS for trend
P=NS for trend
NS%
.0 mm
P
P
PFFR. Abbreviations as in Figures 1 and 2.
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362ACE rates. In support of this second explanation, com-
ared with patients with optimal post-stent FFR, patients
ith suboptimal post-stent FFR not only had significantly
igher rates of revascularization (14.8% vs. 4.9%, p 
.001), but also higher rates of myocardial infarction (4.9%
s. 0.9%, p  0.001) (16,22). We speculate that the higher
ate of myocardial infarction in patients with suboptimal
FR after bare-metal stenting resulted from new plaque
upture associated with proximal diffuse atheroma rather
han restenosis or stent thrombosis. To what degree the
tented segment itself contributes to the final hyperemic
radient (and thus FFR) in the vessel is likely variable and
epends on the stent diameter, how well the stent is
eployed, and the remaining bulk of atheroma proximal to
he stent. It is likely that both explanations contribute to the
elationship of baseline FFR, stent diameter, and outcomes.
It is not surprising that most of the incremental prognos-
ic value of baseline FFR with respect to MACE is seen in
atients with stent diameter 3 mm. Interestingly, longer
tent length and larger MLD were also significant predic-
ors of MACE. It is well known that longer BMS lengths
re associated with restenosis and thus can contribute to
ACE (23). The finding that larger rather than smaller
LD was a predictor of MACE is somewhat surprising.
his finding may relate to either the known inaccuracies of
uantitative angiographic measures for evaluating lesion
everity or the concept that it may not be lesional stenosis
everity assessed by MLD, but rather the whole vessel
therosclerosis burden more accurately assessed by FFR that
s the better predictor of long-term MACE.
mplications for selection of patients for BMS versus DES.
here has been much recent debate and controversy regard-
ng the association of DES with late and very late stent
hrombosis (1–8,24–30). Taken together, these data sug-
est similar rates of death, myocardial infarction, and
efinite stent thrombosis between DES and BMS. How-
ver, some registries have demonstrated persistent rates of
ate stent thrombosis ranging from 0.2% to 0.6% per year
1,5,27). The American Heart Association, American Col-
ege of Cardiology, and European Society of Cardiology
ave recommended careful selection of patients who receive
ES largely based on whether they can tolerate and afford
ong-term antiplatelet therapy. Our study suggests that in
ddition to these considerations, baseline FFR and stent
iameter can be used to help in the selection of patients who
ay achieve low long-term MACE rates with BMS. As it
s not always clear before stent deployment which patients
ill have post-stent FFR 0.90, baseline FFR and antici-
ated stent diameter could assist in the decision to use a
MS or a DES. Our data indicate that patients with stent
iameter of 3 mm and baseline FFR 0.70 have a signifi-
ant (77%) likelihood of achieving optimal post-stent FFR rith BMS. Using MACE as the outcome variable, patients
eceiving BMS with diameters 3.0 mm and baseline FFR
0.50 have high (40%) MACE rates and therefore should
e considered for DES or bypass surgery, but that those
ith stent diameter 3.0 mm and FFR 0.50 may have
cceptable outcomes (MACE 14%) if treated with BMS.
atients with stent diameter 3.0 mm have MACE rates
10% when treated with BMS regardless of baseline FFR,
otentially obviating the need for DES. Prospective ran-
omized studies are required to precisely answer these
uestions.
tudy limitations. First, as a registry, this study is limited by
he lack of a control arm or randomization. Additionally,
he registry sample size does not allow investigation of
ifferences between individual centers contributing data,
nd the modest number of MACE events limits the number
f predictors that can be employed in the multivariate model
ithout overfitting. However, this dataset is largest of its
ind in patients undergoing BMS deployment with clinical,
ngiographic, FFR, and outcome data. Second, 164 patients
rom our initial multicenter registry were excluded from the
resent analysis due to incomplete data. However, we found
o differences between patients with complete and incom-
lete baseline data with regard to baseline diameter stenosis
72.9% vs. 76.2%, p  NS), baseline FFR (0.60 vs. 0.64,
 NS), post-stent FFR (0.92 vs. 0.93, p  NS), and
roportion of patients with post-stent FFR 0.90 (72% vs.
4%, pNS).Third, potential patient selection bias may be
ntroduced by the fact that all patients in this registry had
ressure wire evaluation, and the pressure wire is usually
sed to evaluate intermediate lesions with less plaque
urden. However, the average lesion diameter stenosis was
3  16%, which is similar to average diameter stenosis of
essels in “real life” registries of consecutive patients under-
oing PCI (31,32). Furthermore, it is known that some of
he contributors to this registry used the pressure wire to
ssess adequate stent deployment and not intermediate
esions. Finally, pressure pullback recordings with intrave-
ous adenosine were not systematically performed.
onclusions
n patients undergoing BMS, baseline FFR and stent
iameter predict post-stent FFR 0.90, and baseline FFR,
tent diameter, stent length, and MLD are predictors of
ACE. Specifically, patients receiving 3-mm diameter
tents with baseline FFR 0.70 have a high likelihood of
chieving post-stent FFR 0.90 and patients receiving
3-mm diameter stents with baseline FFR0.50 have very
igh MACE rates at 6 months. These variables may allow
election of patients who will have excellent long-term
esults with BMS.
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